Cargando…
Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604708/ https://www.ncbi.nlm.nih.gov/pubmed/28955498 http://dx.doi.org/10.1136/rmdopen-2017-000492 |
| _version_ | 1783264906556997632 |
|---|---|
| author | Toussirot, Eric Marotte, Hubert |
| author_facet | Toussirot, Eric Marotte, Hubert |
| author_sort | Toussirot, Eric |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5604708 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56047082017-09-27 Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? Toussirot, Eric Marotte, Hubert RMD Open Treatments BMJ Publishing Group 2017-09-12 /pmc/articles/PMC5604708/ /pubmed/28955498 http://dx.doi.org/10.1136/rmdopen-2017-000492 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| spellingShingle | Treatments Toussirot, Eric Marotte, Hubert Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| title | Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| title_full | Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| title_fullStr | Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| title_full_unstemmed | Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| title_short | Switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| title_sort | switching from originator biological agents to biosimilars: what is the evidence and what are the issues? |
| topic | Treatments |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604708/ https://www.ncbi.nlm.nih.gov/pubmed/28955498 http://dx.doi.org/10.1136/rmdopen-2017-000492 |
| work_keys_str_mv | AT toussiroteric switchingfromoriginatorbiologicalagentstobiosimilarswhatistheevidenceandwhataretheissues AT marottehubert switchingfromoriginatorbiologicalagentstobiosimilarswhatistheevidenceandwhataretheissues |